Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response

Horning, 1984, The natural history of initially untreated low-grade non-Hodgkin’s lymphomas, N Engl J Med, 311, 1471, 10.1056/NEJM198412063112303 Deconinck, 2005, High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS, Blood, 105, 3817, 10.1182/blood-2004-10-3920 Lenz, 2004, Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group, Blood, 104, 2667, 10.1182/blood-2004-03-0982 Sebban, 2006, Blood, 108, 2540, 10.1182/blood-2006-03-013193 Schouten, 2003, High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial, J Clin Oncol, 21, 3918, 10.1200/JCO.2003.10.023 Montoto, 2007, Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study, Leukemia, 21, 2324, 10.1038/sj.leu.2404850 Hosing, 2003, Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma, Ann Oncol, 14, 737, 10.1093/annonc/mdg200 Peniket, 2003, An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation, Bone Marrow Transplant, 31, 667, 10.1038/sj.bmt.1703891 van Besien, 2003, Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma, Blood, 102, 3521, 10.1182/blood-2003-04-1205 Kuruvilla, 2008, Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma, Biol Blood Marrow Transplant, 14, 775, 10.1016/j.bbmt.2008.04.007 Hari, 2008, Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning, Biol Blood Marrow Transplant, 14, 236, 10.1016/j.bbmt.2007.11.004 Shea, 2007, Reduced intensity allogeneic transplantation provides high disease-free and overall survival in patients with advanced idolent NHL and CLL: CALGB 109901, Blood, 110, 150a, 10.1182/blood.V110.11.486.486 Pinana, 2010, Reduced-intensity conditioning HLA-identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials, Haematologica, 95, 1176, 10.3324/haematol.2009.017608 Khouri, 2008, Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab, Blood, 111, 5530, 10.1182/blood-2008-01-136242 Morris, 2004, Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma, Blood, 104, 3865, 10.1182/blood-2004-03-1105 Rezvani, 2008, Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma, J Clin Oncol, 26, 211, 10.1200/JCO.2007.11.5477 Harris, 1994, A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group, Blood, 84, 1361, 10.1182/blood.V84.5.1361.1361 Logan, 2008, Use of biological assignment in hematopoietic stem cell transplantation clinical trials, Clin Trials, 5, 607, 10.1177/1740774508098326 Blood and Marrow Transplantation Clinical Trials Network. Manual of procedures. 2010. Available at: https://web.emmes.com/study/bmt2/MOP.html. Accessed Sept 20, 2010. Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI-Sponsored International Working Group, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Rodriguez, 2003, High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience, Ann Oncol, 14, 1768, 10.1093/annonc/mdg459 Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant, 11, 945, 10.1016/j.bbmt.2005.09.004 Przepiorka, 1995, 1994 Consensus Conference on acute GVHD grading, Bone Marrow Transplant, 15, 825 Lin, 1997, Non-parametric inference for cumulative incidence functions in competing-risks studies, Stat Med, 16, 901, 10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Vigouroux, 2007, Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC), Haematologica, 92, 627, 10.3324/haematol.10924 Robinson, 2002, Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation, Blood, 100, 4310, 10.1182/blood-2001-11-0107 Kusumi, 2005, Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan, Bone Marrow Transplant, 36, 205, 10.1038/sj.bmt.1705027 Tomblyn, 2008, Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 14, 538, 10.1016/j.bbmt.2008.02.014 Magni, 2000, Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion, Blood, 96, 864, 10.1182/blood.V96.3.864 Ladetto, 2001, Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin’s lymphoma, Leukemia, 15, 1941, 10.1038/sj.leu.2402302